HemoSense's INRAtio System Receives Marketing Approval in Canada

  
    
  
  
    
      HemoSense, Inc. (AMEX:HEM) today announced that it has received 
      medical device licenses from Health Canada to market its INRatio® 
      PT/INR monitoring system for point-of-care and patient self testing in 
      Canada. HemoSense expects to formalize distribution relationships during 
      the current fiscal quarter, and begin selling INRatio within Canada in 
      the coming months.
    
    
      “We believe that entry into the Canadian 
      market represents a significant growth opportunity with an estimated 
      600,000 patients on chronic warfarin therapy,” 
      said Timothy Still, executive VP and chief commercial officer of 
      HemoSense. “We are committed to providing 
      convenient and easy-to-use PT/INR monitoring solutions to assist 
      patients in managing their warfarin levels. To further strengthen our 
      ability to expand into international markets, we received ISO 13485 
      certification in July of last year. ISO certification is an 
      internationally recognized quality standard for medical devices, which 
      is mandatory for obtaining commercial approval in a number of countries, 
      including Canada.”
    
    
      Canada's health care system is a group of socialized health insurance 
      plans that provide preventative care and medical treatment coverage to 
      all Canadian citizens.
    
    
      About HemoSense
    
    
      HemoSense is a point-of-care diagnostic healthcare company that 
      develops, manufactures and markets easy-to-use, handheld blood 
      coagulation systems for monitoring patients taking warfarin. The 
      HemoSense INRatio® system, used by healthcare 
      professionals and patients themselves, consists of a small monitor and 
      disposable test strips. It provides accurate and convenient measurement 
      of blood clotting time, or PT/INR values. Routine measurements of PT/INR 
      are necessary for the safe and effective management of the patient’s 
      warfarin dosing. INRatio is sold in the United States and 
      internationally. For more information, visit www.hemosense.com.
    
    
      This press release contains forward-looking statements within the 
      meaning of the U.S. Private Securities Litigation Reform Act of 1995. 
      Statements in this press release regarding the Company's business that 
      are not historical facts may be "forward-looking statements" that 
      involve risks and uncertainties. Specifically, the statements regarding 
      the Company’s ability to formalize 
      distribution relationships during the current fiscal quarter, and begin 
      selling INRatio within Canada in the coming months are forward-looking 
      statements within the meaning of the Safe Harbor. Forward-looking 
      statements are based on management's current, preliminary, expectations 
      and are subject to risks and uncertainties which may cause the actual 
      results to differ materially from the statements contained herein. 
      Further information on the Company's business and risk factors are 
      detailed in its filings with the Securities and Exchange Commission, 
      including its 2006 Form 10-K filed on December 27, 2006. Undue reliance 
      should not be placed on these forward-looking statements, which speak 
      only as of the date they are made. The Company undertakes no obligation 
      to update publicly any forward-looking statements to reflect new 
      information, events or circumstances after the date they were made, or 
      to reflect the occurrence of unanticipated events.
    
    
      HemoSense® and INRatio® 
      are registered trademarks of HemoSense, Inc.